Aucfan Co., Ltd.

As of March 31, 2026, Aucfan Co., Ltd. carries a market capitalization of 3.50B, placing it among publicly traded companies globally. Its enterprise value stands at 333.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aucfan Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, Aucfan Co., Ltd. has 10.52M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Aucfan Co., Ltd. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Aucfan Co., Ltd.'s stock has declined approximately 5.23% over the past 52 weeks. The 50-day moving average sits at 333.70, while the 200-day moving average is 330.05.

As of March 31, 2026, Aucfan Co., Ltd. holds 4.45B in cash and equivalents against 1.28B in total debt, resulting in a net debt position of -2.36B. Total book value stands at 4.05B, with working capital of 3.25B providing operational flexibility.

Aucfan Co., Ltd.'s most recent stock split took place on September 26, 2013 with a 1:5 split ratio.